Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Oncogenic KRAS G12D in the Hematopoietic System Causes NLRP3 Inflammasome Activation Leading to Myeloproliferative Syndrome

Shaima'A Hamarsheh, MSc, BSc, Miriam Erlacher, MD PhD, Lena Osswald, Oliver Gorka, PhD, Justus Duyster, Prof., Olaf Groß, PhD, Claudia Lengerke, MD, Melanie Börries, PhD, Tilman Brummer, PhD, Robert Zeiser, MD

Blood (2018) 132 (Supplement 1): 2618.

https://doi.org/10.1182/blood-2018-99-114161

Published: 2018

Journal Articles

Implementation of a Molecular Tumor Board in Clinical Decision Making at the Medical Center University of Freiburg

Blood (2016) 128 (22): 3579.

https://doi.org/10.1182/blood.V128.22.3579.3579

Published: 2016

Journal Articles

Combined Inhibition of BCR and IGF1R Signaling Leads to Synergistic Apoptosis Induction in Primary CLL Cells in Vitro

Charlotte Schmidt-Salzmann, MD, Niuscha Yaktapour, PhD, Tilman Brummer, PhD, Katja Zirlik, MD, Rainer Claus, MD

Blood (2015) 126 (23): 4168.

https://doi.org/10.1182/blood.V126.23.4168.4168

Published: 2015

Journal Articles

Recipient Dendritic Cells Are Regulated By MiR-146a during Acute GvHD

Natalie Stickel, MSc, Kathrin Hanke, MSc, Martin Köhler, MSc, Gabriele Prinz, Dietmar Pfeifer, Annette Schmitt-Graeff, MD, Tilman Brummer, PhD, Juergen Finke, MD, Justus Duyster, MD PhD, Ulrich Salzer, MD, Robert Zeiser, MD

Blood (2015) 126 (23): 146.

https://doi.org/10.1182/blood.V126.23.146.146

Published: 2015

Journal Articles

Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF Signaling

Maximilian Kordes, Michael Röring, Christoph Heining, Sandra Braun, Barbara Hutter, Daniela Richter, Christina Geörg, Claudia Scholl, Wilfried Roth, Andreas Rosenwald, MD, Eva Geissinger, Christof von Kalle, Dirk Jäger, Benedikt Brors, Wilko Weichert, Carsten Grüllich, Hanno Glimm, Tilman Brummer, PhD, Stefan Fröhling

Blood (2015) 126 (23): 1631.

https://doi.org/10.1182/blood.V126.23.1631.1631

Published: 2015

Journal Articles

Myelodysplastic Syndrome Caused By Activating Kras Mutation in the Non-Hematopoietic Bone Marrow Microenvironment

Lena Osswald, Cornelius Miething, MD, Justus Duyster, MD PhD, Tilman Brummer, PhD, Robert Zeiser, MD

Blood (2015) 126 (23): 359.

https://doi.org/10.1182/blood.V126.23.359.359

Published: 2015

NARROW

Oncogenic KRAS G12D in the Hematopoietic System Causes NLRP3 Inflammasome Activation Leading to Myeloproliferative Syndrome

Implementation of a Molecular Tumor Board in Clinical Decision Making at the Medical Center University of Freiburg

Combined Inhibition of BCR and IGF1R Signaling Leads to Synergistic Apoptosis Induction in Primary CLL Cells in Vitro

Recipient Dendritic Cells Are Regulated By MiR-146a during Acute GvHD

Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF Signaling

Myelodysplastic Syndrome Caused By Activating Kras Mutation in the Non-Hematopoietic Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Oncogenic KRAS G12D in the Hematopoietic System Causes NLRP3 Inflammasome Activation Leading to Myeloproliferative Syndrome

Implementation of a Molecular Tumor Board in Clinical Decision Making at the Medical Center University of Freiburg

Combined Inhibition of BCR and IGF1R Signaling Leads to Synergistic Apoptosis Induction in Primary CLL Cells in Vitro

Recipient Dendritic Cells Are Regulated By MiR-146a during Acute GvHD

Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF Signaling

Myelodysplastic Syndrome Caused By Activating Kras Mutation in the Non-Hematopoietic Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only